Recherche en endocrinologie et diabète

The Effect of Colestimide on Visceral Fat Mass and Cytokine Levels in Patients with Metabolic Syndrome

Tatsuya Suzuki, Masao Hashimoto, Shoko Futami-Suda, Yoshimasa Igari, Kentaro Watanabe, Hiroshi Nakano, Joan Auwerx, Mitsuhiro Watanabe and Kenzo Oba

The Effect of Colestimide on Visceral Fat Mass and Cytokine Levels in Patients with Metabolic Syndrome

Bile acid–binding resins (BABRs) improve hyperglycemia in patients with type 2 diabetes, and the BABR colesevelam has been approved by the U.S. Food and Drug Administration for use as an antihyperglycemic agent. Colestimide (colestilan) is a new type of anion resin that increases the number of hepatic low-density lipoprotein receptors and decreases serum cholesterol levels by promoting the excretion of bile acids and inhibiting the absorption of cholesterol in the intestine; with these changes, the serum level of low-density lipoprotein cholesterol decreases.